Can a new drug combo fight childhood brain tumors that Won't stop growing?

NCT ID NCT07732413

Not yet recruiting Disease control Sponsor: Lumos Pharma Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether an experimental drug called NLG802, taken as a pill, can be safely combined with the chemotherapy drug temozolomide for children and young adults (ages 5 to 21) with progressive brain or spinal cord cancer. The study aims to find the highest safe dose of the combination and to understand how the body processes the drugs. Participants must have a tumor that has returned or not responded to prior treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called NLG802 (indoximod prodrug) taken by mouth, combined with the chemotherapy drug temozolomide
What this could lead to: If it works, this could point toward a new treatment option for children with brain tumors that have stopped responding to standard therapy.
What could go wrong: This is an early-phase trial with only 30 participants, so the drug may not prove safe or effective. Side effects from the combination are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates